UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 18, 2023 |
CORBUS PHARMACEUTICALS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-37348 |
46-4348039 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
500 River Ridge Drive |
|
|||
Norwood, Massachusetts |
|
02062 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: (617) 963-0100 |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common Stock, par value $0.0001 per share |
|
CRBP |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 18, 2023, the Company held its Annual Meeting. The matters voted on at the Annual Meeting were: (1) the election of directors, (2) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 and (3) the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers. The final voting results were as follows:
1. The election of each of Yuval Cohen, Alan Holmer, Avery W. Catlin, Peter Salzmann, John Jenkins, Rachelle Jacques, Anne Altmeyer, and Yong Ben as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term.
The votes were cast for this matter as follows:
Nominees |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
Yuval Cohen |
|
273,627 |
|
40,390 |
|
1,633,476 |
Alan Holmer |
|
277,778 |
|
36,239 |
|
1,633,476 |
Avery W. Catlin |
|
279,436 |
|
34,581 |
|
1,633,476 |
Rachelle Jacques |
|
258,401 |
|
55,616 |
|
1,633,476 |
John Jenkins |
|
280,600 |
|
33,417 |
|
1,633,476 |
Peter Salzmann |
|
278,204 |
|
35,813 |
|
1,633,476 |
Anne Altmeyer |
|
280,813 |
|
33,204 |
|
1,633,476 |
Yong Ben |
|
281,040 |
|
32,977 |
|
1,633,476 |
2. The proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved based upon the following votes:
Votes For |
|
Votes Against |
|
Abstentions |
1,806,011 |
|
126,343 |
|
15,139 |
3. The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company’s named executive officers as described in the Company’s definitive proxy statement:
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
244,160 |
|
60,487 |
|
9,370 |
|
1,633,476 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CORBUS PHARMACEUTICALS HOLDINGS, INC. |
|
|
|
|
Date: |
May 19, 2023 |
By: |
/s/ Yuval Cohen |
|
|
|
Name: Yuval Cohen |